Topical Cannabinoid Composition for Vitiligo Repigmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vitiligo are inadequate in addressing the autoimmune response and skin depigmentation, leading to chronic and psychologically traumatic conditions, with limited effectiveness in repigmentation and potential side effects.
Innovation Solution
A topical composition containing cannabidiol (CBD) and cannabigerol (CBG) at specific weight percentages, sourced naturally or synthetically, in various forms such as gels, sprays, or ointments, applied twice daily to affected skin areas, which may be nano- or micro-encapsulated, potentially combined with hyaluronic acid derivatives and plant extracts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for vitiligo are used, then skin depigmentation can be addressed, but the autoimmune response is not adequately treated and side effects occur
Solution Approach 1:
The patent changes the chemical parameters of the treatment by using cannabinoids (CBD and CBG) instead of conventional treatments like corticosteroids or immunomodulators. This parameter change allows the treatment to address autoimmune response through cannabinoid receptor interaction, achieving therapeutic effects without the harmful side effects of conventional medications.
Solution Approach 2:
The patent introduces cannabinoids as intermediary substances that mediate between the immune system and skin pigmentation. Cannabinoids interact with the endocannabinoid system in the skin, acting as a bridge to regulate immune response and promote melanocyte function, thereby treating both autoimmune aspects and depigmentation without direct suppression or harsh intervention.
2Reliability
If conventional treatments are applied, then some repigmentation may occur, but the condition remains chronic and psychologically traumatic
Solution Approach 1:
The patent employs continuous topical application of cannabinoid compositions to maintain sustained therapeutic action on the skin. This continuous delivery system ensures constant presence of active ingredients at the treatment site, promoting progressive repigmentation over time and reducing the chronic nature of the condition by maintaining persistent immune modulation and melanocyte stimulation.
Solution Approach 2:
The patent applies cannabinoid treatments preliminarily to affected skin areas before significant depigmentation becomes irreversible. By initiating treatment early in the disease progression, the composition can prevent further melanocyte destruction and promote repigmentation before the condition becomes chronic and resistant to treatment, thereby reducing overall treatment time and psychological impact.
3Reliability
If topical composition with high cannabinoid concentration is used, then repigmentation improvement is significant, but the composition complexity increases
Solution Approach 1:
The patent uses composite material formulation by combining cannabinoids (CBD and CBG) with carrier substances such as oils, creams, or gels. This composite approach allows high concentrations of active cannabinoids to be delivered effectively while the carrier materials provide stability, solubility, and controlled release, thereby maintaining significant repigmentation improvement without excessive composition complexity.
Solution Approach 2:
The cannabinoid composition is designed with multi-functionality, where the same formulation addresses multiple aspects of vitiligo treatment: immune modulation, anti-inflammatory action, and melanocyte stimulation. This universal approach consolidates multiple therapeutic functions into a single composition, reducing overall treatment complexity while maintaining significant repigmentation improvement through the dose-response effect of cannabinoids.
Data Source
AI summary
A method to treat the skin condition vitiligo is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol, at a concentration of 3%-20% by weight of the composition onto the affected skin area of a subject in need thereof. Application may be twice (2) daily for about six (6) weeks. Cannabidiol and cannabigerol may be sourced naturally or synthetically.